Upcoming events – United seeks a Distinct hit, and Biogen nears a rare catalyst
A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.
United finds a seventh way to serve up treprostinil
Extending a pulmonary hypertension drug’s lifecycle could help battle generic erosion, but investors might have been looking for a more transformative deal.
Mid and small caps provide another rocky ride in the second quarter
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Mid and small caps provide another rocky ride in the second quarter
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Pharma tightens its belt on jobs in 2016 as markets fall
Big pharma swings the axe as sales per employee falls and big biotech could be forced to follow suit.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.